Science

Loay Kassem: Breast saving surgery without radiotherapy could be the new standard for EBC

Loay Kassem/X

Feb 27, 2025, 17:42

Loay Kassem: Breast saving surgery without radiotherapy could be the new standard for EBC

Loay Kassem, Assistant Professor of Clinical Oncology at Kasr AlAiny School of Medicine, Cairo, shared his recent article on LinkedIn:“You can do breast saving surgery without radiotherapy for some patients with early breast cancer.
20 years ago, this would have been considered a crime. Today, this could be the new standard. I will tell you why.

Postmenopausal women with very early breast cancers (pT1 N0) who are ER+ and receive endocrine therapy have very low recurrence rates. This is why some recent studies tested whether or not to give post op radiotherapy in such patients.
I am proud to be among a great team who conducted a systematic review and meta analysis of 7 trials and 4860 patients to answer this question.

Our results are clear.
Adding radiotherapy in such patients can reduce local and nodal recurrence rates (which are already low) but not cancer mortality or distant metastases.

Thanks to the wonderful team Emad Shash, Amira Mohamed Taha, Dalal Salem, Hanaa Abdelmoneim, Yehya Khlidj, Sara Adel, Khaled Abouelmagd, Sanskriti Chaplain and Dang Nguyen.”

Adjuvant radiotherapy in postmenopausal women with early-stage ER-positive breast cancer: A systematic review and meta-analysis

Authors: Amira M Taha et al.

Loay Kassem: Breast saving surgery without radiotherapy could be the new standard for EBC

Amira M Taha Amira MOHAMED TAHA Breast Cancer cancer Dalal Salem Emad Shash fight against cancer Global awareness Global fight against cancer Hanaa abdelmoneim Khaled Abouelmagd Loay Kassem OncoDaily Oncology post op radiotherapy postmenopausal women Sara Adel Yehya Khlidj

FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Standard of Care as Perioperative Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

New Paper Alert Real-Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON-2 Retrospective Experience

Highlights from TTLC2025

KIMMTRAK (Tebentafusp) uses in Cancer: Dosages, Indications, Expectations and more

Senator Edward Markey in Response to OncoDaily About Pediatric Cancer Funding